IVIEW Therapeutics Initiates Phase 1/2 Clinical Trial of IVW-1001, a First-in-Class TRPM8 Agonist for Dry Eye Disease, in the United States

▎WuXi AppTec Content Team Report

On June 25, iView Therapeutics announced that the clinical trial of its Class 1 innovative drug IVW-1001 for the treatment of dry eye disease has been initiated in the United States, with the first subject dosed. According to the press release from iView Therapeutics,IVW-1001 is a novel TRPM8 cold receptor agonist designed to treat the signs and symptoms of dry eye disease.。

Dry eye syndrome is a common and complex ophthalmic condition that affects millions of people worldwide. iVIEW Therapeutics, Inc. has developed a Class 1 innovative drug.IVW-1001, through the mechanism of TRPM8 cold receptor agonist, offers a promising novel therapeutic option targeting the underlying cause of dry eye disease.. In addition, this investigational drug adopts an innovative route of administration through eyelid wiping.

The first-in-human (FIH) clinical trial of IVW-1001 has been initiated in the United States and will be conducted across more than 10 clinical centers in the U.S. with the aim of rigorously evaluating the safety, tolerability, and efficacy of IVW-1001. The iView Therapeutics press release noted that the commencement of participant dosing in the Phase 1/2 clinical trial marks a significant advancement in iView Therapeutics' mission to develop innovative solutions for patients suffering from dry eye disease, particularly for those patients whose symptoms are not improved by artificial tears.

Chief Medical Advisor and Ophthalmologist Leading the Clinical Development of IVW-1001 ProjectHouman Hemmati, M.D.Said: "In our Phase 1/2 clinical trial, dosing the first patient subject is an exciting and crucial step. Our focus remains on comprehensively evaluating the safety and potential efficacy of IVW-1001. The TRPM8 agonist in this study offers an innovative approach to treating dry eye disease, and we are committed to advancing this program to address unmet clinical needs for patients worldwide."

Co-founder, Chairman and CEO of iVIEW Therapeutics, Inc.Dr. Liang Bo"We are delighted to initiate the clinical study of IVW-1001 and commence dosing in the first subject. This milestone underscores our pioneering commitment to treating dry eye disease and highlights the potential of our novel TRPM8 activation mechanism for dry eye treatment. We look forward to the progress of this trial and the new insights it will provide into dry eye therapy."